• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).

作者信息

Witzig T E, LaPlant B, Habermann T M, McPhail E, Inwards D J, Micallef I N, Colgan J P, Nowakowski G S, Ansell S M, Johnston P B

机构信息

Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.

Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.

出版信息

Blood Cancer J. 2017 Jun 23;7(6):e576. doi: 10.1038/bcj.2017.57.

DOI:10.1038/bcj.2017.57
PMID:28649983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5520404/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d494/5520404/d7b701114eab/bcj201757f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d494/5520404/d7b701114eab/bcj201757f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d494/5520404/d7b701114eab/bcj201757f1.jpg

相似文献

1
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).依维莫司联合RCHOP方案治疗初治弥漫性大B细胞淋巴瘤24个月时无事件生存率高：NCCTG N1085（联盟）的更新结果
Blood Cancer J. 2017 Jun 23;7(6):e576. doi: 10.1038/bcj.2017.57.
2
Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤的代谢肿瘤体积与治疗反应
Hematol Oncol. 2019 Aug;37(3):308-309. doi: 10.1002/hon.2612. Epub 2019 Apr 26.
3
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.依维莫司联合R-CHOP-21方案治疗初治弥漫性大B细胞淋巴瘤（NCCTG 1085 [联盟]）：1期安全性、有效性及可行性试验结果
Lancet Haematol. 2016 Jul;3(7):e309-16. doi: 10.1016/S2352-3026(16)30040-0. Epub 2016 Jun 5.
4
Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.一项针对连续入选的、未经筛选的老年初发弥漫性大B细胞淋巴瘤患者队列，对R-CHOP计划剂量强度对预后影响的大型回顾性分析结果。
Br J Haematol. 2016 May;173(3):487-91. doi: 10.1111/bjh.13619. Epub 2015 Jul 29.
5
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.利妥昔单抗密集化疗联合或不联合大剂量化疗和自体干细胞移植治疗高危弥漫性大 B 细胞淋巴瘤（DLCL04）：一项多中心、开放标签、随机、对照、3 期研究的最终结果。
Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
6
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.来那度胺联合环磷酰胺、多柔比星、长春新碱、泼尼松和利妥昔单抗治疗未经治疗的老年弥漫性大 B 细胞淋巴瘤患者安全有效：一项由意大利淋巴瘤基金会开展的 I 期研究。
Haematologica. 2013 Nov;98(11):1732-8. doi: 10.3324/haematol.2013.085134. Epub 2013 Jun 28.
7
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.在预后不良的未经治疗的弥漫性大 B 细胞非霍奇金淋巴瘤的非常老年患者中，使用利妥昔单抗的剂量调整的输注环磷酰胺、多柔比星、长春新碱和泼尼松化疗的活性和安全性。
Cancer. 2011 Mar 1;117(5):964-73. doi: 10.1002/cncr.25582. Epub 2010 Oct 19.
8
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.体重指数对接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱、泼尼松治疗的美国弥漫性大B细胞淋巴瘤退伍军人发热性中性粒细胞减少症发病率及治疗相关死亡率的影响
Br J Haematol. 2014 Dec;167(5):699-702. doi: 10.1111/bjh.13026. Epub 2014 Jul 15.
9
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.ACVBP 强化化疗联合利妥昔单抗对比标准 CHOP 联合利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤（LNH03-2B）：一项开放标签、随机、3 期临床试验。
Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4.
10
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.依鲁替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤患者。
Blood. 2011 Oct 13;118(15):4053-61. doi: 10.1182/blood-2011-02-336990. Epub 2011 Jun 14.

引用本文的文献

1
Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303.接受一线R-CHOP治疗的弥漫性大B细胞淋巴瘤老年患者的年龄和体能状态与不良事件的关联：联盟151930，III期试验CALGB 50303的二次分析
J Geriatr Oncol. 2025 Mar;16(2):102185. doi: 10.1016/j.jgo.2025.102185. Epub 2025 Jan 13.
2
The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects.mTOR在B细胞淋巴瘤中的作用：生物学及治疗学方面
Int J Mol Sci. 2023 Sep 14;24(18):14110. doi: 10.3390/ijms241814110.
3

本文引用的文献

1
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.随机对照试验比较 R-CHOP 与高危弥漫大 B 细胞淋巴瘤患者的高剂量序贯化疗。
J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.
2
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.依维莫司联合R-CHOP-21方案治疗初治弥漫性大B细胞淋巴瘤（NCCTG 1085 [联盟]）：1期安全性、有效性及可行性试验结果
Lancet Haematol. 2016 Jul;3(7):e309-16. doi: 10.1016/S2352-3026(16)30040-0. Epub 2016 Jun 5.
3
Molecular classification and therapeutics in diffuse large B-cell lymphoma.
弥漫性大B细胞淋巴瘤的分子分类与治疗
Front Mol Biosci. 2023 Feb 3;10:1124360. doi: 10.3389/fmolb.2023.1124360. eCollection 2023.
4
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.阿伐度胺（CC - 122）、CC - 223、CC - 292与利妥昔单抗联合用于复发/难治性弥漫性大B细胞淋巴瘤患者的Ib期研究。
EJHaem. 2022 Jan 14;3(1):139-153. doi: 10.1002/jha2.375. eCollection 2022 Feb.
5
New agents and regimens for diffuse large B cell lymphoma.弥漫性大B细胞淋巴瘤的新型药物和治疗方案
J Hematol Oncol. 2020 Dec 14;13(1):175. doi: 10.1186/s13045-020-01011-z.
6
[The prognostic significance of lymphocyte/monocyte ratio in diffuse large B cell lymphoma].[淋巴细胞/单核细胞比值在弥漫性大B细胞淋巴瘤中的预后意义]
Zhonghua Xue Ye Xue Za Zhi. 2019 May 14;40(5):436-438. doi: 10.3760/cma.j.issn.0253-2727.2019.05.018.
7
Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.二甲双胍的使用对新发弥漫性大 B 细胞淋巴瘤和滤泡性淋巴瘤患者结局的影响。
Br J Haematol. 2019 Sep;186(6):820-828. doi: 10.1111/bjh.15997. Epub 2019 May 28.
8
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤的维持治疗。
Curr Treat Options Oncol. 2018 Jul 21;19(9):45. doi: 10.1007/s11864-018-0561-x.
9
Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells.用抗坏血酸上调 TET 活性可诱导淋巴瘤细胞的表观遗传修饰。
Blood Cancer J. 2017 Jul 21;7(7):e587. doi: 10.1038/bcj.2017.65.
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
随机、双盲、III 期试验：恩杂鲁胺对比安慰剂在一线治疗高危弥漫性大 B 细胞淋巴瘤缓解后的患者中的应用。
J Clin Oncol. 2016 Jul 20;34(21):2484-92. doi: 10.1200/JCO.2015.65.7171. Epub 2016 May 23.
4
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.来那度胺联合 R-CHOP 克服了新诊断弥漫性大 B 细胞淋巴瘤中非生发中心 B 细胞表型的不良预后影响：一项 II 期研究。
J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.
5
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者：一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
6
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.来那度胺联合 R-CHOP21 方案治疗未经治疗的老年弥漫性大 B 细胞淋巴瘤患者：REAL07 开放标签、多中心、Ⅱ期临床试验结果。
Lancet Oncol. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3. Epub 2014 May 13.
7
Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.R(X)CHOP时代弥漫性大B细胞淋巴瘤的预后因素
Ann Oncol. 2014 Nov;25(11):2124-2133. doi: 10.1093/annonc/mdu109. Epub 2014 Mar 13.
8
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.在接受免疫化疗治疗的弥漫性大 B 细胞淋巴瘤患者中，24 个月时无事件生存是疾病相关结局的一个强有力的终点。
J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18.
9
Diffuse large B-cell lymphoma-treatment approaches in the molecular era.弥漫性大 B 细胞淋巴瘤的分子时代治疗方法。
Nat Rev Clin Oncol. 2014 Jan;11(1):12-23. doi: 10.1038/nrclinonc.2013.197. Epub 2013 Nov 12.
10
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.硼替佐米联合 CHOP-利妥昔单抗方案治疗初治弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤。
J Clin Oncol. 2011 Feb 20;29(6):690-7. doi: 10.1200/JCO.2010.31.1142. Epub 2010 Dec 28.